Millipore (MIL) 8-K Results of Operations and Financial Condition

Exhibit 99.1

Millipore Reports Strong Fourth Quarter and

Full Year Revenue Growth

Improved execution, leadership in fast growing markets, and new products drive higher organic growth

BILLERICA, Mass. –January 26, 2006 – Millipore Corporation (NYSE:MIL), a leading provider of products and services that improve productivity in the laboratory and in biopharmaceutical manufacturing, today reported financial results for its fiscal 2005 fourth quarter and full year ended December 31, 2005.

Revenues for the fourth quarter grew 14 percent totaling $256.3 million. In constant currency, quarterly revenue growth was 19 percent, led by 24 percent growth from Millipore’s Bioprocess division and 11 percent growth from its Bioscience division. Excluding the impact of acquisitions, constant currency revenue growth in the fourth quarter was 15 percent, compared to organic growth of 1 percent in the fourth quarter of 2004.

For the full year, revenues grew 12 percent totaling $991.0 million. In constant currency, 2005 revenue growth also was 12 percent. This full year performance was led by 15 percent growth in the Bioprocess division and 7 percent growth in the Bioscience division. Excluding the impact of acquisitions, constant currency revenue growth was 10 percent for the year, compared to organic growth of 6 percent in 2004.

Millipore reported fourth quarter net income of $1.0 million, or $0.02 per share, compared to net income of $24.8 million or $0.49 per share in the fourth quarter of 2004. The Company’s fourth quarter results included a one-time tax expense of $30.6 million for the repatriation of foreign earnings and a tax benefit of $3.4 million from the reversal of tax valuation allowances. Fourth quarter results also included expenses of approximately $8.4 million relating to the Company’s manufacturing consolidation strategy, amortization of acquired intangibles, and professional fees associated with the repatriation of foreign earnings. Excluding these items and applying the appropriate tax rate, non-GAAP net income in the fourth quarter grew 30 percent to $32.7 million, or $0.62 per share, compared to non-GAAP net income of $25.1 million, or $0.50 per share in the fourth quarter of 2004.

“We are successfully executing our new strategy, which is enabling us to improve our operational performance and accelerate our growth,” said Martin Madaus, Millipore’s President, Chairman and CEO. “Both divisions met or exceeded our expectations and we delivered on the promises made earlier this year to improve the Company’s financial performance. The key drivers of this growth are improved execution from a substantially revamped management team, the contribution of new acquisitions, and the Company’s participation in strong growth markets where it is an industry leader.

“Over the past 12 months, we have begun to transform Millipore into a Company that is moving faster and successfully executing our strategy of being a leading supplier to the biotechnology and pharmaceutical industries. We have reorganized from three divisions to two, improved our R&D capabilities, broadened our product portfolio with two acquisitions and a strategic alliance, and revamped our global supply chain to drive profitability improvements over the next four years. As we look forward to 2006, we are focused on maintaining the momentum generated this year and on relentlessly pursing initiatives that support our strategy and improve performance.”

Fourth Quarter Highlights

• Record growth in constant currency of 19 percent; 15 percent excluding the impact of acquisitions

• Operational improvements from global supply chain initiatives yielding higher gross margins

• Strengthened financial flexibility by borrowing $450 million as part of the Company’s repatriation of foreign earnings

• Non-GAAP EBITDA margins increase from 19 percent to 22 percent

“During the fourth quarter, we continued to make progress on our key financial metrics, lowering our accounts receivable day sales outstanding to 67 days, a year-over-year improvement of 6 days,” said Kathy Allen, Corporate Vice President & CFO of Millipore. “We also lowered our inventory days of supply to its lowest level in over a year, a significant accomplishment considering our build of inventory in support of our factory consolidation program.”

Quarterly revenue growth by geography($ millions):

Revenues by Geographic Area	Q4 2005		Q4 2004		% Growth		% Growth Constant Currency
Americas	$	109.8	$	91.1	20	%	20	%
Europe		103.4		92.4	12	%	22	%
Asia/Pacific		43.1		41.9	3	%	11	%
Total	$	256.3	$	225.4	14	%	19	%

Quarterly revenue growth by division($ millions):

Revenues by Division	Q4 2005		Q4 2004		% Growth		% Growth Constant Currency
Bioprocess	$	157.6	$	132.1	19	%	24	%
Bioscience		98.7		93.3	6	%	11	%
Total	$	256.3	$	225.4	14	%	19	%

Fiscal 2005 Highlights

• Constant currency revenue growth of 12%; 10% excluding the impact of acquisitions

• Increased non-GAAP gross margins due to global supply chain improvements

• Improved non-GAAP EBITDA margins from approximately 21 percent to 23 percent

• Introduced 40 new products, completed two acquisitions and formed one alliance

• Restructured from three to two divisions

• Extended leadership in faster growing markets

For full year 2005, Millipore reported net income of $80.2 million, or $1.55 per share, compared to net income of $105.6 million, or $2.10 per share in 2004. On a non-GAAP basis, the Company reported fiscal 2005 net income of $133.3 million, or $2.58 per share, compared to 2004 non-GAAP net income of $109.8 million, or $2.19 per share. Cash flow from operations was $185.1 million in 2005, compared to $167.4 million in 2004.

Annual revenue growth by geography($ millions):

Revenues by Geographic Area	2005		2004		% Growth		% Growth Constant Currency
Americas	$	419.6	$	367.3	14	%	13	%
Europe		399.6		353.6	13	%	13	%
Asia/Pacific		171.8		162.4	6	%	7	%
Total	$	991.0	$	883.3	12	%	12	%

Annual revenue growth by division($ millions):

Revenues by Division	2005		2004		% Growth		% Growth Constant Currency
Bioprocess	$	601.4	$	519.9	16	%	15	%
Bioscience		389.6		363.4	7	%	7	%
Total	$	991.0	$	883.3	12	%	12	%

Use of Non-GAAP Financial Measures

In addition to analyzing U.S. GAAP financial results, management also analyzes “non-GAAP” financial measures as we believe these measures may allow investors a better understanding of the underlying business trends in evaluating our results.

“Constant currency” is a non-GAAP measure whereby foreign currency balances are translated, in all periods presented, at Millipore’s predetermined budgeted exchange rates for 2005, thereby excluding the impact of fluctuations in the actual foreign currency rates. Non-GAAP earnings per share reflect U.S. GAAP results, translated at actual rates of exchange, adjusted for unusual or non-operating items. Non-GAAP earnings also exclude intangible asset amortization as we believe this may help investors evaluate the Company’s operating results in a consistent manner over time notwithstanding the ongoing acquisition of new businesses.

We encourage investors to carefully consider our results under GAAP, as well as our non-GAAP disclosures and the reconciliation between these presentations to more fully understand our business. Reconciliations between GAAP and non-GAAP adjustments are presented on the following pages.

Quarterly Earnings Call

Millipore will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters at 4:45 p.m. Eastern Time today. The call can be accessed through Millipore’s website:http://www.millipore.com. A replay of the call will be archived on the Investor Relations section of the website and will also be available via telephone by dialing (800) 642-1687 or (706) 645-9291 and entering confirmation code: 4415612. The telephonic replay will be available beginning at 8:00 p.m. ET on January 26, 2006 until 8:00 p.m. ET on January 31, 2006.

About Millipore

Millipore is a leading bioprocess and bioscience products and services company, organized into two divisions. The Bioprocess division offers solutions that optimize development and manufacturing of biologics. The Bioscience division provides high performance products and application insights that improve laboratory productivity. Millipore has a deep understanding of its customers’ research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company employs approximately 4,800 people worldwide and posted revenues of $991 million in 2005.

For additional information on Millipore Corporation, please visit its website at:www.millipore.com.

Forward Looking Statements:

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed

in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore’s future operating results include, without limitation, foreign exchange rates; regulatory delay in the approval of new therapeutics and their ultimate commercial success; competitive factors such as new membrane technology; lack of availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general and in the bioscience and bioprocess markets in particular; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; the inability to successfully integrate acquired businesses; the inability to realize the expected benefits of development, marketing and other alliances; difficulties inherent in transferring or outsourcing of manufacturing operations; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore’s filings with the SEC.

Investor Contact	Media Contact
Joshua Young	Thomas Anderson
Director, Investor Relations	Vice President
(978) 715-1527	Corporate Communications
(800) 225-3384	(978) 715-1043
joshua_young@millipore.com	(800) 225-3384
	thomas_anderson@millipore.com

Millipore Corporation

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)

	Three Months Ended						Twelve Months Ended
	December 31, 2005			December 31, 2004			December 31, 2005			December 31, 2004
Net sales	$	256,332		$	225,402		$	991,031		$	883,263
Cost of sales		124,933			110,573			472,023			412,129
Gross profit		131,399			114,829			519,008			471,134
Selling, general and administrative expenses		76,879			71,268			304,696			267,540
Research and development expenses		16,929			15,302			66,052			62,485
Purchased intangibles amortization		1,566			749			4,333			3,256
Purchased in-process research and development		—			—			3,149			—
Operating income		36,025			27,510			140,778			137,853
Interest income		1,264			848			3,466			2,073
Interest expense		(1,690	)		(2,031	)		(6,711	)		(9,447	)
Income before provision for income taxes		35,599			26,327			137,533			130,479
Provision for income taxes		34,582			1,489			57,365			24,923
Net income	$	1,017		$	24,838		$	80,168		$	105,556
Diluted income per share	$	0.02		$	0.49		$	1.55		$	2.10
Diluted weighted average shares outstanding		52,964			50,341			51,659			50,201

Millipore Corporation

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

	December 31, 2005		December 31, 2004
ASSETS
Current assets:
Cash and cash equivalents	$	537,052	$	152,144
Marketable securities		113,839		—
Accounts receivable, net		188,130		181,911
Inventories		153,030		143,714
Deferred income taxes		66,008		54,247
Other current assets		14,300		8,840
Total current assets		1,072,359		540,856
Property, plant and equipment, net		371,249		351,004
Deferred income taxes		71,544		85,197
Intangible assets, net		43,421		19,584
Goodwill		82,718		9,433
Other assets		8,986		7,745
Total assets	$	1,650,277	$	1,013,819
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	79,587	$	66,970
Accrued expenses and other current liabilities		165,668		96,040
Total current liabilities		245,255		163,010
Long-term debt		552,285		147,000
Other liabilities		60,218		64,959
Shareholders' equity		792,519		638,850
Total liabilities and shareholders' equity	$	1,650,277	$	1,013,819

Millipore Corporation

Condensed Consolidated Statements of Income

and Reconciliation of Non-GAAP Adjustments (1)

(In thousands, except per share data)

(Unaudited)

	Three Months Ended December 31, 2005
	GAAP			Non-GAAP Adjustments			Non-GAAP
Net sales	$	256,332		$	—		$	256,332
Cost of sales		124,933			(5,796	)(2)		119,137
Gross profit		131,399			5,796			137,195
Margin %		51.3	%					53.5	%
Selling, general and administrative expenses		76,879			(1,066	)(3)		75,813
Research and development expenses		16,929			—			16,929
Purchased intangibles amortization		1,566			(1,566	)(4)		—
Operating income		36,025			8,428			44,453
Operating margin %		14.1	%					17.3	%
Interest income		1,264			—			1,264
Interest expense		(1,690	)		—			(1,690	)
Income before provision for income taxes		35,599			8,428			44,027
Provision for income taxes		34,582			(23,243	)(5)		11,339
Income tax rate		97.1	%					25.8	%
Net income	$	1,017		$	31,671		$	32,688
Diluted income per share	$	0.02		$	0.60		$	0.62
Diluted weighted average shares outstanding		52,964			52,964			52,964

(1) Non-GAAP adjustments include unusual or non-recurring items. We calculate and disclose these non-GAAP measures because we believe that these measures may allow investors a better understanding of the underlying trends in evaluating our results. We include purchased intangibles amortization as a non-GAAP adjustment as we believe this may help investors evaluate our operating results in a consistent manner over time notwithstanding the ongoing acquisition of new businesses.

(2) Cost of sales non-GAAP adjustments represent $5,531 related to our manufacturing consolidation strategy and $265 related to inventory fair value adjustments from business acquisitions.

(3) Selling, general and administrative non-GAAP adjustments include $1,066 of professional fees associated with the repatriation of foreign earnings.

(4) Purchased intangibles amortization is adjusted for non-GAAP presentation.

(5) Provision for income taxes was decreased by $30,634 for future tax payments related to the repatriation of foreign earnings offset by the release of $3,177 of tax valuation allowances. The effective income tax rate used in the calculation of non-GAAP net income differs from the effective income tax rate for GAAP purposes due primarily to the geographic mix of profits.

Millipore Corporation

Condensed Consolidated Statements of Income

and Reconciliation of Non-GAAP Adjustments (1)

(In thousands, except per share data)

(Unaudited)

	Twelve Months Ended December 31, 2005
	GAAP			Non-GAAP Adjustments			Non-GAAP
Net sales	$	991,031		$	—		$	991,031
Cost of sales		472,023			(14,714	)(2)		457,309
Gross profit		519,008			14,714			533,722
Margin %		52.4	%					53.9	%
Selling, general and administrative expenses		304,696			(15,833	)(3)		288,863
Research and development expenses		66,052			(478	)(4)		65,574
Purchased intangibles amortization		4,333			(4,333	)(5)		—
Purchased in-process research and development		3,149			(3,149	)(6)		—
Operating income		140,778			38,507			179,285
Operating margin %		14.2	%					18.1	%
Interest income		3,466			—			3,466
Interest expense		(6,711	)		—			(6,711	)
Income before provision for income taxes		137,533			38,507			176,040
Provision for income taxes		57,365			(14,587	)(7)		42,778
Income tax rate		41.7	%					24.3	%
Net income	$	80,168		$	53,094		$	133,262
Diluted income per share	$	1.55		$	1.03		$	2.58
Diluted weighted average shares outstanding		51,659			51,659			51,659

(1) Non-GAAP adjustments include unusual or non-recurring items. We calculate and disclose these non-GAAP measures because we believe that these measures may allow investors a better understanding of the underlying trends in evaluating our results. We include purchased intangibles amortization as a non-GAAP adjustment as we believe this may help investors evaluate our operating results in a consistent manner over time notwithstanding the ongoing acquisition of new businesses.

(2) Cost of sales non-GAAP adjustments represent $12,542 related to our manufacturing consolidation strategy and $2,172 related to inventory fair value adjustments from business acquisitions.

(3) Selling, general and administrative non-GAAP adjustments include $1,066 of professional fees associated with the repatriation of foreign earnings, $11,572 of executive termination costs and $3,195 of severance related to the divisional consolidation.

(4) Research and development non-GAAP adjustments include $478 of severance related to the divisional consolidation.

(5) Purchased intangibles amortization is adjusted for non-GAAP presentation.

(6) Purchased in-process research and development associated with the NovAseptic acquisition.

(7) Provision for income taxes was decreased by $30,634 for future tax payments related to the repatriation of foreign earnings offset by the release of $3,177 of tax valuation allowances. The effective income tax rate used in the calculation of non-GAAP net income differs from the effective income tax rate for GAAP purposes due primarily to the geographic mix of profits.

Millipore Corporation

Condensed Consolidated Statements of Income

and Reconciliation of Non-GAAP Adjustments (1)

(In thousands, except per share data)

(Unaudited)

	Three Months Ended December 31, 2004
	GAAP			Non-GAAP Adjustments			Non-GAAP
Net sales	$	225,402		$	—		$	225,402
Cost of sales		110,573			—			110,573
Gross profit		114,829			—			114,829
Margin %		50.9	%					50.9	%
Selling, general and administrative expenses		71,268			(4,347	)(2)		66,921
Research and development expenses		15,302			—			15,302
Purchased intangibles amortization		749			(749	)(3)		—
Operating income		27,510			5,096			32,606
Operating margin %		12.2	%					14.5	%
Interest income		848			—			848
Interest expense		(2,031	)		—			(2,031	)
Income before provision for income taxes		26,327			5,096			31,423
Provision for income taxes		1,489			4,799	(4)		6,288
Income tax rate		5.7	%					20.0	%
Net income	$	24,838		$	297		$	25,135
Diluted income per share	$	0.49		$	0.01		$	0.50
Diluted weighted average shares outstanding		50,341			50,341			50,341

(1) Non-GAAP adjustments include unusual or non-recurring items. We calculate and disclose these non-GAAP measures because we believe that these measures may allow investors a better understanding of the underlying trends in evaluating our results. We include purchased intangibles amortization as a non-GAAP adjustment as we believe this may help investors evaluate our operating results in a consistent manner over time notwithstanding the ongoing acquisition of new businesses.

(2) Selling, general and administrative non-GAAP adjustments include $1,343 of executive termination costs and $3,004 for the write-off of intangible assets.

(3) Purchased intangibles amortization is adjusted for non-GAAP presentation.

(4) The effective income tax rate used in the calculation of non-GAAP net income differs from the effective income tax rate for GAAP purposes due primarily to the geographic mix of profits.

Millipore Corporation

Condensed Consolidated Statements of Income

and Reconciliation of Non-GAAP Adjustments (1)

(In thousands, except per share data)

(Unaudited)

	Twelve Months Ended December 31, 2004
	GAAP			Non-GAAP Adjustments			Non-GAAP
Net sales	$	883,263		$	—		$	883,263
Cost of sales		412,129			—			412,129
Gross profit		471,134			—			471,134
Margin %		53.3	%					53.3	%
Selling, general and administrative expenses		267,540			(7,412	)(2)		260,128
Research and development expenses		62,485			—			62,485
Purchased intangibles amortization		3,256			(3,256	)(3)		—
Operating income		137,853			10,668			148,521
Operating margin %		15.6	%					16.8	%
Interest income		2,073			—			2,073
Interest expense		(9,447	)		—			(9,447	)
Income before provision for income taxes		130,479			10,668			141,147
Provision for income taxes		24,923			6,445	(4)		31,368
Income tax rate		19.1	%					22.2	%
Net income	$	105,556		$	4,223		$	109,779
Diluted income per share	$	2.10		$	0.09		$	2.19
Diluted weighted average shares outstanding		50,201			50,201			50,201

(1) Non-GAAP adjustments include unusual or non-recurring items. We calculate and disclose these non-GAAP measures because we believe that these measures may allow investors a better understanding of the underlying trends in evaluating our results. We include purchased intangibles amortization as a non-GAAP adjustment as we believe this may help investors evaluate our operating results in a consistent manner over time notwithstanding the ongoing acquisition of new businesses.

(2) Selling, general and administrative non-GAAP adjustments include $4,408 of executive termination costs and $3,004 for the write-off of intangible assets.

(3) Purchased intangibles amortization is adjusted for non-GAAP presentation.

(4) The effective income tax rate used in the calculation of non-GAAP net income differs from the effective income tax rate for GAAP purposes due primarily to the geographic mix of profits.